Drug Trial Radar · NCT07715084
Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 25, 2027
Primary completion
Jan 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Azafaros B.V.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 4 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 96-week, open-label, Phase 2 study to evaluate the efficacy and safety of Nizubaglustat (AZ-3102) in patients with Gaucher disease type 3 (GD3).
Conditions
- Gaucher Disease Type 3
Interventions
AZ-3102Drug
Daily oral intake of AZ-3102 orodispersible tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in hemoglobin levels from BaselineTime frame: 24 weeks
- Change in platelet count from BaselineTime frame: 24 weeks
- Change in total spleen volume from BaselineTime frame: 24 weeks
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
SMS Medical College Jaipur
Jaipur, India
Maula a Azad medical college Delhi
New Delhi, India
Sir Ganga Ram Hospital
New Delhi, India
University of Child Health Sciences and the Children's Hospital
Lahore, Pakistan
Clininal Trial Unit, Rehman Medical Institute
Peshawar, Pakistan
Gazi University Medical Faculty Hospital
Yenimahalle, Turkey (Türkiye)
Ege Universitesi Tip Fakultesi Hastanesi
Bornova, İzmir, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.